Aarti Drugs Limited

BSE: 524348 NSE: AARTIDRUGS
Aarti Drugs Limited - chemicals and materials in Dist Thane, Maharashtra, India. FY 2026 financials and compliance.
CIN L37060MH1984PLC055433 Incorporated 28 September 1984 ROC Mumbai HQ Dist Thane, Maharashtra, India
Active Listed - NSE: AARTIDRUGS · BSE: 524348 Public Limited Company chemicals and materials
Data last updated
Revenue · FY 2026
₹2,565.31 Cr
▲ 7.47% YoY
Computed EBITDA · FY 2026
₹311.58 Cr
▲ 2.69% YoY
Net profit · FY 2026
₹194.94 Cr
▲ 15.97% YoY
Authorised capital
₹120 Cr
Registered with MCA
Paid-up capital
₹91.27 Cr
Issued & subscribed
Open charges
₹1,570 Cr
Satisfied ₹1,214.54 Cr
Company age
42 yrs
Est. 1984
Employees · EPFO
1,012
Latest available

About Aarti Drugs Limited

Data last updated: 17 December 2025

Aarti Drugs Limited is a public limited company based in Dist Thane, Maharashtra, India. It specialises in specialty chemicals, a part of the broader chemicals and materials sector. Incorporated on 28 September 1984, the company has been in operation for over 42 years.

Registered with ROC Mumbai under CIN L37060MH1984PLC055433. Listed on BSE: 524348 and NSE: AARTIDRUGS.

Capital: an authorised share capital of ₹120 Cr and a paid-up capital of ₹91.27 Cr. Formerly known as Aarti Drugs Private Limited. It is led by directors including Prakash Moreshwar Patil and Narendra Jagannath Salvi.

Last AGM: 24 September 2025. Financial statements filed for year ended 31 March 2025. Office: Plot No 198 Midc Tarapurtal.Palghar Village Pamtermbhi, Dist Thane, Maharashtra, India – 401506.

As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹2,565.31 Cr, a growth of 7.47% compared to the previous year. The net worth stands at ₹1,549.23 Cr (up 13.14% YoY). Total assets are valued at ₹2,815.26 Cr (up 9.34% YoY).

The company has a workforce of approximately 1,012 employees as per the latest available data. Its group structure includes 2 subsidiaries.

The company is associated with 2 brands - Aarti Drugs Ltd, Aarti Drugs. As per MCA filings, the company has open charges of ₹1,570 Cr and satisfied charges of ₹1,214.54 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website aartidrugs.co.in.

Company Details of Aarti Drugs Limited
CIN L37060MH1984PLC055433
Registration Number 055433
Incorporation Date 28 September 1984
ROC Mumbai
Listing Status Listed (BSE: 524348, NSE: AARTIDRUGS)
Company Status Active
Date of Last AGM 24 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Prakash Moreshwar Patil Managing Director Harshit Manilal Savla Managing Director Rashesh Chandrakant Gogri Managing Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    aartidrugs.co.in
  • Social Media
    Locked
  • Registered Address
    Plot No 198 Midc Tarapurtal.Palghar Village Pamtermbhi, Dist Thane, Maharashtra, India – 401506
  • Industry
    Chemicals and Materials, Specialty Chemicals
Company report
Aarti Drugs Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Aarti Drugs Limited report

Financials, compliance, directors, charges, ownership and filings for Aarti Drugs Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Aarti Drugs Limited

Aarti Drugs Limited has one previous CIN (Corporate Identification Number): U37060MH1990PLC055433. The current CIN is L37060MH1984PLC055433, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L37060MH1984PLC055433 Current
U37060MH1990PLC055433 Previous

Associated Brands with Aarti Drugs Limited

Aarti Drugs Limited operates two associated brands: Aarti Drugs Ltd and Aarti Drugs. These brands represent Aarti Drugs Limited's diversified market presence and brand portfolio.

Brand Description Website
Aarti Drugs
APIs, intermediates, steroids, and formulations are manufactured. aartidrugs.co.in
Aarti Drugs Ltd
Manufacturing of Active Pharmaceutical Ingredients, Pharma Intermediates, and Specialty Chemicals in India. aartidrugs.com

Competitors & Alternatives of Aarti Drugs Limited

Brands and companies operating in the same space as Aarti Drugs Limited include Concord Biotech, BDR Pharmaceuticals Internationals, Almac Group and 7 more.

Competitor Description Location Founded
Concord Biotech Concord Biotech APIs and enzymes are manufactured through fermentation by the CDMO. Ahmedabad, India, India 2000
BDR Pharmaceuticals Internationals BDR Pharmaceuticals Internationals APIs and finished products are developed and manufactured. Mumbai, India, India 2003
Almac Group Almac Group Integrated CDMO services for biopharma R&D and manufacturing are offered. Craigavon, United Kingdom, United Kingdom 2001
Indoco Remedies Indoco Remedies APIs manufacturing and formulation services are provided in therapeutic segments. Mumbai, India, India 1947
Pharmaceutics International Pharmaceutics International Pharmaceutical dosage forms are manufactured by this CDMO. Hunt Valley, United States, United States 1994
Aurobindo Pharma Aurobindo Pharma Generic biocatalytic solutions are provided for pharmaceutical applications. Hyderabad, India, India 1986
Seqens Seqens Contract manufacturing services for small molecules and peptides are provided. Ecully, France, France 2003
Asymchem Asymchem APIs and peptides are developed and manufactured by Asymchem. Morrisville, United States, United States 1995
Aptuit Aptuit Contract research and development services for small molecules are offered. Greenwich, United States, United States 2004
Continuus Pharma Continuus Pharma MIT-Novartis spinoff offering continuous manufacturing solutions to remove the proverbial wall between API and FDF manufacturing in small molecule development Woburn, United States, United States 2012

Business Activity of Aarti Drugs Limited

Aarti Drugs Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Aarti Drugs Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Aarti Drugs Limited

Aarti Drugs Limited is audited by Gokhale & Sathe, Chartered Accountants (ICAI peer reviewed, certificate valid till 2027-02-28) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
Gokhale & Sathe, Chartered Accountants (ICAI peer reviewed, certificate valid till 2027-02-28) FY 2026 Declaration of unmodified opinion

Board of Directors and KMP of Aarti Drugs Limited

Aarti Drugs Limited currently reports 12 directors and 1 key managerial person. 17 former directors have served the organization.

Current Directors and KMP
Name Designation Appointment Date Tenure Status
Prakash Moreshwar Patil
Also directs: Aarti Life Science Llp
Managing Director 05 Jan 1985 41 Years 6 Months Current
Narendra Jagannath Salvi
Also directs: Aarti Pharmalabs Limited, Aarti Pharmachem Limited
Director 25 Aug 2020 5 Years 10 Months Current
Ankit Vikram Paleja
Also directs: Capacit'e Infraprojects Limited
Director 13 Oct 2021 4 Years 9 Months Current
Neha Rajen Gada
Also directs: Pinnacle Life Science Private Limited, Infineon Capital Advisors Llp, Sejal Glass Limited and 5 more
Director 09 May 2022 4 Years 2 Months Current
Harit Pragji Shah
Also directs: Harshit Ventures Limited Liability Partnership, Aarti Life Science Llp, Aarti Speciality Chemicals Limited and 5 more
Whole-Time Director 15 Sep 1995 30 Years 9 Months Current
Harshit Manilal Savla
Also directs: Harshit Ventures Limited Liability Partnership, Aarti Life Science Llp, Aarti Speciality Chemicals Limited and 5 more
Managing Director 02 Jan 1987 39 Years 6 Months Current
Showing 6 of 13 current directors and KMP. View all directors and KMP

Financials of Aarti Drugs Limited FY 2026 filings available

Aarti Drugs Limited reported revenue of ₹2,565.31 Cr (up 7.47% YoY) for FY 2026.

Revenue · FY 2026
₹2,565.31 Cr ▲ 7.47%
Profit · FY 2026
₹194.94 Cr ▲ 15.97%
Computed EBITDA · FY 2026
₹311.58 Cr ▲ 2.69%
Revenue₹ Cr · Consolidated01,0002,0003,000FY 2020: ₹1,806 Cr1,806FY 2020FY 2021: ₹2,155 Cr · +19.3% YoY2,155+19.3%FY 2021FY 2022: ₹2,489 Cr · +15.5% YoY2,489+15.5%FY 2022FY 2023: ₹2,716 Cr · +9.1% YoY2,716+9.1%FY 2023FY 2024: ₹2,529 Cr · -6.9% YoY2,529-6.9%FY 2024FY 2025: ₹2,387 Cr · -5.6% YoY2,387-5.6%FY 2025FY 2026: ₹2,565 Cr · +7.5% YoY2,565+7.5%FY 2026
Net Profit₹ Cr · Consolidated0100200300FY 2020: ₹141 Cr141FY 2020FY 2021: ₹280 Cr · +98.3% YoY280+98.3%FY 2021FY 2022: ₹205 Cr · -26.9% YoY205-26.9%FY 2022FY 2023: ₹166 Cr · -18.8% YoY166-18.8%FY 2023FY 2024: ₹172 Cr · +3.1% YoY172+3.1%FY 2024FY 2025: ₹168 Cr · -2% YoY168-2%FY 2025FY 2026: ₹195 Cr · +16% YoY195+16%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year0250500750Q1'25: ₹555 Cr · -16% YoY555-16%Q1'25Q2'25: ₹598 Cr · -6.7% YoY598-6.7%Q2'25Q3'25: ₹557 Cr · -8.1% YoY557-8.1%Q3'25Q4'25: ₹677 Cr · +9.2% YoY677+9.2%Q4'25Q1'26: ₹591 Cr · +6.3% YoY591+6.3%Q1'26Q2'26: ₹653 Cr · +9.1% YoY653+9.1%Q2'26Q3'26: ₹602 Cr · +8.1% YoY602+8.1%Q3'26Q4'26: ₹720 Cr · +6.4% YoY720+6.4%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹2,565.31 Cr ₹2,387.03 Cr ₹2,528.58 Cr ₹2,716.05 Cr ₹2,488.65 Cr ₹2,154.78 Cr ₹1,806.09 Cr
Other Income ₹2.39 Cr ₹16.36 Cr ₹4.03 Cr ₹2.19 Cr ₹11.32 Cr ₹4.53 Cr ₹1.48 Cr
Total Income ₹2,567.7 Cr ₹2,403.39 Cr ₹2,532.61 Cr ₹2,718.24 Cr ₹2,499.97 Cr ₹2,159.31 Cr ₹1,807.57 Cr
Cost of Materials Consumed ₹1,504.01 Cr ₹1,438.3 Cr ₹1,571.98 Cr ₹1,768.97 Cr ₹1,666.36 Cr ₹1,221.52 Cr ₹1,141.92 Cr
Purchases of Stock-in-Trade ₹115.08 Cr ₹84.34 Cr ₹80.23 Cr ₹121.29 Cr ₹108.57 Cr ₹111.24 Cr ₹88.32 Cr
Changes in Inventories -₹37 Lakh ₹19.46 Cr ₹25.51 Cr -₹1.75 Cr -₹86.08 Cr -₹11.72 Cr -₹51.28 Cr
Employee Benefit Expense ₹129.32 Cr ₹112.1 Cr ₹102.34 Cr ₹92.02 Cr ₹82.81 Cr ₹80.5 Cr ₹69.36 Cr
Finance Costs ₹33.71 Cr ₹35.87 Cr ₹33.52 Cr ₹33.29 Cr ₹20.75 Cr ₹22.96 Cr ₹33.73 Cr
Depreciation & Amortisation ₹66.97 Cr ₹55.78 Cr ₹51.45 Cr ₹50.32 Cr ₹50.05 Cr ₹49.88 Cr ₹48.75 Cr
Other Expenses ₹508.08 Cr ₹445.77 Cr ₹432.05 Cr ₹429.92 Cr ₹387.55 Cr ₹316.14 Cr ₹295.95 Cr
Total Expenses ₹2,356.8 Cr ₹2,191.62 Cr ₹2,297.08 Cr ₹2,494.06 Cr ₹2,230.01 Cr ₹1,790.52 Cr ₹1,626.75 Cr
Profit Before Exceptional Items & Tax ₹210.9 Cr ₹211.77 Cr ₹235.53 Cr ₹224.18 Cr ₹269.96 Cr ₹368.79 Cr ₹180.82 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹22 Lakh ₹4.47 Cr
Profit Before Tax ₹210.9 Cr ₹211.77 Cr ₹235.53 Cr ₹224.18 Cr ₹269.96 Cr ₹369.01 Cr ₹185.29 Cr
Total Tax Expense ₹15.96 Cr ₹43.67 Cr ₹63.94 Cr ₹57.82 Cr ₹64.96 Cr ₹88.61 Cr ₹43.89 Cr
Net Profit ₹194.94 Cr ₹168.1 Cr ₹171.59 Cr ₹166.36 Cr ₹205 Cr ₹280.4 Cr ₹141.4 Cr
  attributable to Owners ₹194.92 Cr ₹168.16 Cr ₹171.42 Cr ₹166.31 Cr ₹205.04 Cr ₹280.41 Cr ₹141.4 Cr
  attributable to NCI ₹2.03 Lakh -₹6.15 Lakh ₹17.25 Lakh ₹5 Lakh -₹4.28 Lakh -₹1.47 Lakh -₹21,000
Other Comprehensive Income ₹3.2 Cr ₹1.59 Cr ₹6 Lakh -₹1.5 Cr ₹68 Lakh ₹3.41 Cr ₹1.77 Cr
Total Comprehensive Income ₹198.14 Cr ₹169.69 Cr ₹171.65 Cr ₹164.86 Cr ₹205.68 Cr ₹283.81 Cr ₹143.17 Cr
EBITDA (computed) ₹311.58 Cr ₹303.42 Cr ₹320.5 Cr ₹307.79 Cr ₹340.76 Cr ₹441.63 Cr ₹263.3 Cr
Basic EPS ₹21.36 ₹18.35 ₹18.56 ₹17.97 ₹22.12 ₹30.09 ₹60.57
Diluted EPS ₹21.36 ₹18.35 ₹18.56 ₹17.97 ₹22.12 ₹30.09 ₹60.57
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹2,815.26 Cr ₹2,574.68 Cr ₹2,432.36 Cr ₹2,421.4 Cr
Non-current Assets ₹1,347.49 Cr ₹1,236.32 Cr ₹1,111.64 Cr ₹929.04 Cr
Current Assets ₹1,467.77 Cr ₹1,338.36 Cr ₹1,320.72 Cr ₹1,492.36 Cr
Property, Plant & Equipment ₹1,068.27 Cr ₹856.25 Cr ₹808.16 Cr ₹675.43 Cr
Inventories ₹490.78 Cr ₹472.93 Cr ₹485.89 Cr ₹516.29 Cr
Trade Receivables ₹829.87 Cr ₹751.18 Cr ₹704.55 Cr ₹864.84 Cr
Cash & Equivalents ₹7.27 Cr ₹4.58 Cr ₹6.74 Cr ₹8.96 Cr
Equity (Net Worth) ₹1,549.23 Cr ₹1,369.34 Cr ₹1,281.96 Cr ₹1,192.66 Cr
Equity Share Capital ₹91.27 Cr ₹91.27 Cr ₹91.94 Cr ₹92.6 Cr
Borrowings (Non-current) ₹256.87 Cr ₹284 Cr ₹275.33 Cr ₹204.68 Cr
Borrowings (Current) ₹317.96 Cr ₹328.24 Cr ₹287.09 Cr ₹401.84 Cr
Total Debt (computed) ₹574.83 Cr ₹612.24 Cr ₹562.42 Cr ₹606.52 Cr
Current Liabilities ₹922.25 Cr ₹836.97 Cr ₹795.54 Cr ₹932.98 Cr
Total Liabilities ₹1,266.03 Cr ₹1,205.34 Cr ₹1,150.4 Cr ₹1,228.74 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹253.54 Cr ₹244.58 Cr ₹358.92 Cr ₹134.2 Cr ₹69.64 Cr
Investing Cash Flow -₹173.41 Cr -₹164.63 Cr -₹223.65 Cr -₹163.97 Cr -₹148.86 Cr
Financing Cash Flow -₹77.44 Cr -₹82.12 Cr -₹136.03 Cr ₹16.54 Cr ₹92.02 Cr
Capital Expenditure ₹173.32 Cr ₹177.16 Cr ₹226.33 Cr ₹164.67 Cr ₹143.68 Cr
Free Cash Flow (computed) ₹80.22 Cr ₹67.42 Cr ₹132.59 Cr -₹30.47 Cr -₹74.04 Cr
Dividends Paid ₹18.17 Cr ₹9.06 Cr ₹9.27 Cr ₹9.4 Cr ₹9.51 Cr
Net Change in Cash ₹2.69 Cr -₹2.17 Cr -₹76 Lakh -₹13.23 Cr ₹12.8 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹720.3 Cr ₹601.71 Cr ₹652.79 Cr ₹590.51 Cr ₹676.76 Cr ₹556.6 Cr ₹598.33 Cr ₹555.34 Cr ₹619.99 Cr ₹605.94 Cr ₹641.54 Cr ₹661.11 Cr
Other Income ₹76 Lakh ₹1.23 Cr ₹9 Lakh ₹31 Lakh ₹1.87 Cr ₹11.9 Cr ₹1.48 Cr ₹1.11 Cr ₹1.08 Cr ₹1.67 Cr ₹68 Lakh ₹60 Lakh
Total Income ₹721.06 Cr ₹602.94 Cr ₹652.88 Cr ₹590.82 Cr ₹678.63 Cr ₹568.5 Cr ₹599.81 Cr ₹556.45 Cr ₹621.07 Cr ₹607.61 Cr ₹642.22 Cr ₹661.71 Cr
Cost of Materials Consumed ₹427.19 Cr ₹334.52 Cr ₹385.06 Cr ₹357.25 Cr ₹375.14 Cr ₹369.79 Cr ₹345.58 Cr ₹347.79 Cr ₹366.64 Cr ₹401.07 Cr ₹395.66 Cr ₹408.61 Cr
Purchases of Stock-in-Trade ₹33.32 Cr ₹22.51 Cr ₹30.64 Cr ₹28.61 Cr ₹23.13 Cr ₹14.11 Cr ₹29.57 Cr ₹17.54 Cr ₹20.33 Cr -₹21.7 Cr ₹42.18 Cr ₹39.42 Cr
Changes in Inventories -₹10.09 Cr ₹29.61 Cr -₹7.41 Cr -₹12.47 Cr ₹38.64 Cr -₹32.51 Cr ₹18.85 Cr -₹5.51 Cr ₹10.13 Cr ₹25.86 Cr -₹8.81 Cr -₹1.68 Cr
Employee Benefit Expense ₹32.28 Cr ₹33.16 Cr ₹33.07 Cr ₹30.8 Cr ₹31.35 Cr ₹27.76 Cr ₹26.56 Cr ₹26.43 Cr ₹25.87 Cr ₹25.55 Cr ₹25.45 Cr ₹25.47 Cr
Finance Costs ₹8.16 Cr ₹9.29 Cr ₹7.7 Cr ₹8.56 Cr ₹9.16 Cr ₹9.07 Cr ₹8.93 Cr ₹8.71 Cr ₹9.13 Cr ₹7.6 Cr ₹8.25 Cr ₹8.54 Cr
Depreciation & Amortisation ₹18.04 Cr ₹17.95 Cr ₹16.26 Cr ₹14.72 Cr ₹14.88 Cr ₹13.8 Cr ₹13.72 Cr ₹13.38 Cr ₹13.58 Cr ₹12.66 Cr ₹12.61 Cr ₹12.6 Cr
Other Expenses ₹141.8 Cr ₹126.88 Cr ₹127.15 Cr ₹112.24 Cr ₹115.18 Cr ₹115.72 Cr ₹110.72 Cr ₹104.13 Cr ₹111.21 Cr ₹105.02 Cr ₹110.61 Cr ₹105.22 Cr
Total Expenses ₹650.7 Cr ₹573.92 Cr ₹592.47 Cr ₹539.71 Cr ₹607.48 Cr ₹517.74 Cr ₹553.93 Cr ₹512.47 Cr ₹556.89 Cr ₹556.06 Cr ₹585.95 Cr ₹598.18 Cr
Profit Before Exceptional Items & Tax ₹70.36 Cr ₹29.02 Cr ₹60.41 Cr ₹51.11 Cr ₹71.15 Cr ₹50.76 Cr ₹45.88 Cr ₹43.98 Cr ₹64.18 Cr ₹51.55 Cr ₹56.27 Cr ₹63.53 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹70.36 Cr ₹29.02 Cr ₹60.41 Cr ₹51.11 Cr ₹71.15 Cr ₹50.76 Cr ₹45.88 Cr ₹43.98 Cr ₹64.18 Cr ₹51.55 Cr ₹56.27 Cr ₹63.53 Cr
Total Tax Expense ₹15.1 Cr -₹11.53 Cr ₹15.25 Cr -₹2.86 Cr ₹8.38 Cr ₹13.67 Cr ₹10.92 Cr ₹10.71 Cr ₹16.87 Cr ₹14.84 Cr ₹16.67 Cr ₹15.56 Cr
Net Profit ₹55.26 Cr ₹40.55 Cr ₹45.16 Cr ₹53.97 Cr ₹62.77 Cr ₹37.09 Cr ₹34.96 Cr ₹33.27 Cr ₹47.31 Cr ₹36.71 Cr ₹39.6 Cr ₹47.97 Cr
  attributable to Owners ₹55.19 Cr ₹40.54 Cr ₹45.28 Cr ₹53.91 Cr ₹62.86 Cr ₹37.05 Cr ₹35.01 Cr ₹33.24 Cr ₹47.37 Cr ₹36.67 Cr ₹39.59 Cr -
  attributable to NCI ₹6.55 Lakh ₹1.16 Lakh -₹11.91 Lakh ₹6.24 Lakh -₹9.15 Lakh ₹4.67 Lakh -₹4.57 Lakh ₹2.89 Lakh -₹6.19 Lakh ₹3.92 Lakh ₹1 Lakh -
Other Comprehensive Income ₹2.77 Cr ₹31 Lakh ₹0 ₹11 Lakh ₹1.28 Cr -₹46 Lakh ₹35 Lakh ₹42 Lakh ₹6 Lakh ₹0 ₹0 ₹0
Total Comprehensive Income ₹58.03 Cr ₹40.86 Cr ₹45.16 Cr ₹54.08 Cr ₹64.05 Cr ₹36.63 Cr ₹35.31 Cr ₹33.69 Cr ₹47.37 Cr ₹36.71 Cr ₹39.6 Cr ₹47.97 Cr
EBITDA (computed) ₹96.56 Cr ₹56.26 Cr ₹84.37 Cr ₹74.39 Cr ₹95.19 Cr ₹73.63 Cr ₹68.53 Cr ₹66.07 Cr ₹86.89 Cr ₹71.81 Cr ₹77.13 Cr ₹84.67 Cr
Basic EPS ₹6.05 ₹4.44 ₹4.95 ₹5.91 ₹6.88 ₹4.06 ₹3.83 ₹3.62 ₹5.15 ₹3.99 ₹4.29 ₹5.18
Diluted EPS ₹6.05 ₹4.44 ₹4.95 ₹5.91 ₹6.88 ₹4.06 ₹3.83 ₹3.62 ₹5.15 ₹3.99 ₹4.29 ₹5.18
Latest 12 quarters shown of 24 on record.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹2,260.39 Cr ₹2,173.65 Cr ₹2,266.91 Cr ₹2,497.97 Cr ₹2,251.17 Cr ₹1,914.89 Cr ₹1,634.92 Cr
Other Income ₹2.59 Cr ₹13.58 Cr ₹4.18 Cr ₹2.23 Cr ₹4.77 Cr ₹6.42 Cr ₹1.06 Cr
Total Income ₹2,262.98 Cr ₹2,187.23 Cr ₹2,271.09 Cr ₹2,500.2 Cr ₹2,255.94 Cr ₹1,921.31 Cr ₹1,635.98 Cr
Cost of Materials Consumed ₹1,401.85 Cr ₹1,358.34 Cr ₹1,466.57 Cr ₹1,702.44 Cr ₹1,524.56 Cr ₹1,127.79 Cr ₹1,078.8 Cr
Purchases of Stock-in-Trade ₹45.51 Cr ₹44.34 Cr ₹35.86 Cr ₹47.01 Cr ₹58.31 Cr ₹43.17 Cr ₹40.53 Cr
Changes in Inventories ₹6.62 Cr ₹22 Cr ₹26.77 Cr -₹6.72 Cr -₹77.94 Cr -₹9.08 Cr -₹53.94 Cr
Employee Benefit Expense ₹96.27 Cr ₹85.25 Cr ₹80.98 Cr ₹74.99 Cr ₹69.32 Cr ₹69.29 Cr ₹60.1 Cr
Finance Costs ₹26.38 Cr ₹29.68 Cr ₹30.16 Cr ₹32.53 Cr ₹20.06 Cr ₹22.61 Cr ₹32.2 Cr
Depreciation & Amortisation ₹55.64 Cr ₹47.79 Cr ₹47.67 Cr ₹47.29 Cr ₹47.39 Cr ₹47.6 Cr ₹46.67 Cr
Other Expenses ₹449.4 Cr ₹401.08 Cr ₹390.6 Cr ₹397.85 Cr ₹358.74 Cr ₹282.44 Cr ₹265.03 Cr
Total Expenses ₹2,081.67 Cr ₹1,988.48 Cr ₹2,078.61 Cr ₹2,295.39 Cr ₹2,000.44 Cr ₹1,583.82 Cr ₹1,469.39 Cr
Profit Before Exceptional Items & Tax ₹181.31 Cr ₹198.75 Cr ₹192.48 Cr ₹204.81 Cr ₹255.5 Cr ₹337.49 Cr ₹166.59 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹22 Lakh ₹8.38 Cr
Profit Before Tax ₹181.31 Cr ₹198.75 Cr ₹192.48 Cr ₹204.81 Cr ₹255.5 Cr ₹337.71 Cr ₹174.97 Cr
Total Tax Expense ₹12.09 Cr ₹41.44 Cr ₹50.6 Cr ₹52 Cr ₹60.5 Cr ₹80 Cr ₹39.3 Cr
Net Profit ₹169.22 Cr ₹157.31 Cr ₹141.88 Cr ₹152.81 Cr ₹195 Cr ₹257.71 Cr ₹135.67 Cr
Other Comprehensive Income ₹2.47 Cr ₹1.13 Cr ₹1.39 Cr -₹1.42 Cr ₹66 Lakh ₹3.41 Cr ₹1.78 Cr
Total Comprehensive Income ₹171.69 Cr ₹158.44 Cr ₹143.27 Cr ₹151.39 Cr ₹195.66 Cr ₹261.12 Cr ₹137.45 Cr
EBITDA (computed) ₹263.33 Cr ₹276.22 Cr ₹270.31 Cr ₹284.63 Cr ₹322.95 Cr ₹407.7 Cr ₹245.46 Cr
Basic EPS ₹18.54 ₹17.18 ₹15.35 ₹16.50 ₹21.04 ₹27.65 ₹58.12
Diluted EPS ₹18.54 ₹17.18 ₹15.35 ₹16.50 ₹21.04 ₹27.65 ₹58.12
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹2,381.6 Cr ₹2,272.79 Cr ₹2,171.62 Cr ₹2,195.5 Cr
Non-current Assets ₹1,168.84 Cr ₹1,092.23 Cr ₹990.6 Cr ₹845.96 Cr
Current Assets ₹1,212.76 Cr ₹1,180.56 Cr ₹1,181.02 Cr ₹1,349.54 Cr
Property, Plant & Equipment ₹970.31 Cr ₹759.57 Cr ₹720.33 Cr ₹634.17 Cr
Inventories ₹405.35 Cr ₹407.23 Cr ₹441.77 Cr ₹477.73 Cr
Trade Receivables ₹732.41 Cr ₹701.72 Cr ₹643.95 Cr ₹801.68 Cr
Cash & Equivalents ₹3.57 Cr ₹3.28 Cr ₹2.72 Cr ₹2.68 Cr
Equity (Net Worth) ₹1,404.79 Cr ₹1,251.35 Cr ₹1,175.21 Cr ₹1,114.3 Cr
Equity Share Capital ₹91.27 Cr ₹91.27 Cr ₹91.94 Cr ₹92.6 Cr
Borrowings (Non-current) ₹181.7 Cr ₹237.95 Cr ₹238.26 Cr ₹161.89 Cr
Borrowings (Current) ₹238.27 Cr ₹275.97 Cr ₹234.6 Cr ₹371.2 Cr
Total Debt (computed) ₹419.97 Cr ₹513.92 Cr ₹472.86 Cr ₹533.09 Cr
Current Liabilities ₹712.63 Cr ₹705.78 Cr ₹684.6 Cr ₹830.99 Cr
Total Liabilities ₹976.81 Cr ₹1,021.44 Cr ₹996.41 Cr ₹1,081.2 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹254.14 Cr ₹220.08 Cr ₹337.1 Cr ₹162.28 Cr ₹39.9 Cr
Investing Cash Flow -₹127.58 Cr -₹134.92 Cr -₹187.09 Cr -₹131.14 Cr -₹125.36 Cr
Financing Cash Flow -₹126.27 Cr -₹84.6 Cr -₹148.81 Cr -₹30.53 Cr ₹84.11 Cr
Capital Expenditure ₹102.39 Cr ₹137.29 Cr ₹189.32 Cr ₹130.54 Cr ₹126.87 Cr
Free Cash Flow (computed) ₹151.75 Cr ₹82.79 Cr ₹147.78 Cr ₹31.74 Cr -₹86.97 Cr
Dividends Paid ₹18.17 Cr ₹9.06 Cr ₹9.27 Cr ₹9.4 Cr ₹9.51 Cr
Net Change in Cash ₹29 Lakh ₹56 Lakh ₹1.2 Cr ₹61 Lakh -₹1.35 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹631.68 Cr ₹528.8 Cr ₹578.95 Cr ₹520.96 Cr ₹622.96 Cr ₹514.54 Cr ₹543.09 Cr ₹492.96 Cr ₹559.53 Cr ₹538.21 Cr ₹577.54 Cr ₹591.63 Cr
Other Income ₹83 Lakh ₹1.22 Cr ₹15 Lakh ₹38 Lakh ₹1.71 Cr ₹11.37 Cr ₹38 Lakh ₹11 Lakh ₹1.11 Cr ₹1.68 Cr ₹74 Lakh ₹65 Lakh
Total Income ₹632.51 Cr ₹530.02 Cr ₹579.1 Cr ₹521.34 Cr ₹624.67 Cr ₹525.91 Cr ₹543.47 Cr ₹493.07 Cr ₹560.64 Cr ₹539.89 Cr ₹578.28 Cr ₹592.28 Cr
Cost of Materials Consumed ₹399.29 Cr ₹307.25 Cr ₹361.49 Cr ₹333.81 Cr ₹351.48 Cr ₹354.24 Cr ₹327.01 Cr ₹325.49 Cr ₹345.65 Cr ₹329.93 Cr ₹391.97 Cr ₹399.02 Cr
Purchases of Stock-in-Trade ₹12.12 Cr ₹12.34 Cr ₹9.84 Cr ₹11.21 Cr ₹13.49 Cr ₹9.49 Cr ₹11.94 Cr ₹9.42 Cr ₹10.91 Cr ₹5.64 Cr ₹8.07 Cr ₹11.25 Cr
Changes in Inventories -₹5.93 Cr ₹30.18 Cr -₹4.98 Cr -₹12.65 Cr ₹41.09 Cr -₹32.6 Cr ₹23.6 Cr -₹10.09 Cr ₹14.5 Cr ₹28.17 Cr -₹8.62 Cr -₹7.28 Cr
Employee Benefit Expense ₹23.21 Cr ₹25.03 Cr ₹24.74 Cr ₹23.29 Cr ₹23.4 Cr ₹21.04 Cr ₹20.14 Cr ₹20.67 Cr ₹19.94 Cr ₹20.24 Cr ₹20.04 Cr ₹20.66 Cr
Finance Costs ₹6.59 Cr ₹6.95 Cr ₹6.01 Cr ₹6.82 Cr ₹7.48 Cr ₹7.57 Cr ₹7.17 Cr ₹7.46 Cr ₹8.09 Cr ₹6.75 Cr ₹7.55 Cr ₹7.77 Cr
Depreciation & Amortisation ₹14.95 Cr ₹14.87 Cr ₹13.55 Cr ₹12.27 Cr ₹12.21 Cr ₹12.02 Cr ₹11.86 Cr ₹11.71 Cr ₹12.34 Cr ₹11.8 Cr ₹11.78 Cr ₹11.75 Cr
Other Expenses ₹123.72 Cr ₹111.69 Cr ₹112.67 Cr ₹101.34 Cr ₹104.85 Cr ₹102.12 Cr ₹100.86 Cr ₹93.25 Cr ₹99.47 Cr ₹94.49 Cr ₹100.66 Cr ₹96.07 Cr
Total Expenses ₹573.95 Cr ₹508.31 Cr ₹523.32 Cr ₹476.09 Cr ₹554 Cr ₹473.88 Cr ₹502.58 Cr ₹457.91 Cr ₹510.9 Cr ₹497.02 Cr ₹531.45 Cr ₹539.24 Cr
Profit Before Exceptional Items & Tax ₹58.56 Cr ₹21.71 Cr ₹55.78 Cr ₹45.25 Cr ₹70.67 Cr ₹52.03 Cr ₹40.89 Cr ₹35.16 Cr ₹49.74 Cr ₹42.87 Cr ₹46.83 Cr ₹53.04 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹58.56 Cr ₹21.71 Cr ₹55.78 Cr ₹45.25 Cr ₹70.67 Cr ₹52.03 Cr ₹40.89 Cr ₹35.16 Cr ₹49.74 Cr ₹42.87 Cr ₹46.83 Cr ₹53.04 Cr
Total Tax Expense ₹13.6 Cr -₹12.13 Cr ₹14 Cr -₹3.39 Cr ₹9.19 Cr ₹13.5 Cr ₹10.5 Cr ₹8.25 Cr ₹13.6 Cr ₹11.25 Cr ₹12.25 Cr ₹13.5 Cr
Net Profit ₹44.96 Cr ₹33.84 Cr ₹41.78 Cr ₹48.64 Cr ₹61.48 Cr ₹38.53 Cr ₹30.39 Cr ₹26.91 Cr ₹36.14 Cr ₹31.62 Cr ₹34.58 Cr ₹39.54 Cr
Other Comprehensive Income ₹2.47 Cr ₹0 ₹0 ₹0 ₹1.13 Cr ₹0 ₹0 ₹0 ₹1.39 Cr ₹0 ₹0 ₹0
Total Comprehensive Income ₹47.43 Cr ₹33.84 Cr ₹41.78 Cr ₹48.64 Cr ₹62.61 Cr ₹38.53 Cr ₹30.39 Cr ₹26.91 Cr ₹37.53 Cr ₹31.62 Cr ₹34.58 Cr ₹39.54 Cr
EBITDA (computed) ₹80.1 Cr ₹43.53 Cr ₹75.34 Cr ₹64.34 Cr ₹90.36 Cr ₹71.62 Cr ₹59.92 Cr ₹54.33 Cr ₹70.17 Cr ₹61.42 Cr ₹66.16 Cr ₹72.56 Cr
Basic EPS ₹4.93 ₹3.71 ₹4.58 ₹5.33 ₹6.74 ₹4.22 ₹3.33 ₹2.93 ₹3.93 ₹3.44 ₹3.75 ₹4.27
Diluted EPS ₹4.93 ₹3.71 ₹4.58 ₹5.33 ₹6.74 ₹4.22 ₹3.33 ₹2.93 ₹3.93 ₹3.44 ₹3.75 ₹4.27
Latest 12 quarters shown of 25 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Aarti Drugs Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Aarti Drugs Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 55.03%, foreign institutional investors hold 1.58%, domestic institutional investors hold 10.22%, retail and other public shareholders hold 33.18% of Aarti Drugs Limited. The company had 144,946 shareholders on record.

Promoters: 55.03%DII (Domestic Institutional): 10.22%FII (Foreign Institutional): 1.58%Retail & Others: 33.18%
Mar 2026
QUARTER
55.03% Promoters
10.22% DII (Domestic Institutional)
1.58% FII (Foreign Institutional)
33.18% Retail & Others
Promoter holding - history
Now 55.03% · Mar 2026High 62.67% · Jun 2017Low 54.72% · Sep 2025
53%55.8%58.5%61.3%64%Dec 2015Jun 2018Oct 2020Mar 2023Sep 2025Dec 2015: 61.86%Mar 2016: 61.93%Jun 2016: 62.00%Sep 2016: 62.65%Dec 2016: 62.29%Mar 2017: 62.46%Jun 2017: 62.67%Sep 2017: 62.49%Dec 2017: 62.38%Mar 2018: 62.48%Jun 2018: 62.51%Sep 2018: 62.43%Dec 2018: 62.30%Mar 2019: 62.26%Jun 2019: 62.25%Sep 2019: 61.64%Dec 2019: 61.62%Mar 2020: 61.44%Jun 2020: 60.51%Sep 2020: 60.21%Oct 2020: 60.21%Dec 2020: 60.20%Mar 2021: 60.20%Jun 2021: 60.14%Sep 2021: 60.12%Dec 2021: 59.99%Mar 2022: 59.83%Jun 2022: 59.98%Sep 2022: 59.77%Dec 2022: 59.66%Mar 2023: 59.58%Jun 2023: 58.70%Sep 2023: 58.56%Dec 2023: 57.47%Mar 2024: 57.13%Jun 2024: 55.67%Sep 2024: 55.64%Dec 2024: 55.38%Mar 2025: 55.48%Jun 2025: 55.22%Sep 2025: 54.72%Dec 2025: 55.03%Mar 2026: 55.03%62.67%54.72%55.03%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters55.03%55.03%54.72%55.22%55.48%55.38%
Public44.97%44.97%45.28%44.78%44.52%44.62%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters55.03%55.48%57.13%59.58%59.83%60.20%61.44%62.26%62.48%62.46%61.93%
Public44.97%44.52%42.87%40.42%40.17%39.80%38.56%37.74%37.52%37.54%38.07%
Promoter change (YoY, %pts)-0.45-1.65-2.45-0.25-0.37-1.24-0.82-0.22+0.02+0.53-

Board & Governance of Aarti Drugs Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Aarti Drugs Limited has 12 directors - 6 independent and 5 executive. The board is chaired by Prakash Moreshwar Pati.

DirectorPositionOn board sinceListed boards
Prakash Moreshwar Pati Executive Director · CEO-MD · Chairperson 1985-01-05 1
Rashesh Chandrakant Gogri Executive Director · MD 2012-08-16 3
Harshit Manilal Savla Executive Director · MD 1987-01-02 1
Harit Pragji Shah Executive Director 1995-09-15 1
Uday Moreshwar Patil Executive Director 2000-10-18 1
Narendra Jagannath Salvi Non-Executive - Non Independent Director 2020-08-25 2
Ankit Vikram Paleja Non-Executive - Independent Director 2021-10-13 2
Bhaskar Narayan Thorat Non-Executive - Independent Director 2022-05-09 1
Neha Rajen Gada Non-Executive - Independent Director 2022-05-09 4
Hasmukh Bhavanji Dedhia Non-Executive - Independent Director 2024-03-29 2
Ajit Eledath Venugopalan Non-Executive - Independent Director 2024-03-29 1
Sandeep Madhusudan Joshi Non-Executive - Independent Director 2024-03-29 1
Board Committees
CommitteeMembers
Audit Committee Hasmukh Bhavanji Dedhia (Chairperson), Ankit Vikram Paleja, Neha Rajen Gada, Ajit Eledath Venugopalan, Prakash Moreshwar Pati, Rashesh Chandrakant Gogri
Nomination and remuneration committee Neha Rajen Gada (Chairperson), Bhaskar Narayan Thorat, Ankit Vikram Paleja, Prakash Moreshwar Pati
Stakeholders Relationship Committee Ankit Vikram Paleja (Chairperson), Narendra Jagannath Salvi, Harshit Manilal Savla, Harit Pragji Shah
Risk Management Committee Prakash Moreshwar Pati (Chairperson), Rashesh Chandrakant Gogri, Harit Pragji Shah, Harshit Manilal Savla, Uday Moreshwar Patil, Bhaskar Narayan Thorat, Ankit Vikram Paleja, Adhish Prakash Patil, Dhanaji Laxman Kakade
Corporate Social Responsibility Committee Bhaskar Narayan Thorat (Chairperson), Prakash Moreshwar Pati, Rashesh Chandrakant Gogri
Finance and Investment Committee Prakash Moreshwar Pati (Chairperson), Rashesh Chandrakant Gogri, Harit Pragji Shah, Harshit Manilal Savla, Uday Moreshwar Patil

Group Structure of Aarti Drugs Limited

Aarti Drugs Limited has 2 subsidiary companies. This group structure data is as of FY 2024. The corporate group structure reflects Aarti Drugs Limited's business expansion strategy and organizational complexity.

2
Subsidiary companies
Key Subsidiaries
Company Name CIN Shares Held
Aarti Speciality Chemicals U24230MH2019PLC333306 -
Pinnacle Life Science Privat U24232HP2003PTC030912 -

Showing major subsidiaries. Total: 2.

Charges & Borrowings of Aarti Drugs Limited

Open charges
₹1,570 Cr
Satisfied charges
₹1,214.54 Cr
Breakdown by lending institutions
Axis Bank Limited₹1,570.00 Cr
Latest charge details
DateLenderAmountStatus
26 Mar 2011 Axis Bank Limited ₹1,570 Cr Open
25 Jan 2024 Others ₹300 Cr Satisfied
20 Sep 2018 Others ₹64 Cr Satisfied
24 Jun 2016 Others ₹69 Cr Satisfied
21 Dec 2015 The Shamrao Vithal Co Operative Bank Limited ₹25 Cr Satisfied

Total charge records: 58 View all charges

Employees and EPFO Compliance at Aarti Drugs Limited

Aarti Drugs Limited has a workforce of 1,007 employees as of Feb 04, 2025.

Employee count
1,007
Active EPFO establishments
2
Employee growth
4.46%
Premium access

Employee and EPFO history for Aarti Drugs Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Aarti Drugs Limited

Premium access

GST registrations and filing compliance for Aarti Drugs Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Aarti Drugs Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Aarti Drugs Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Aarti Drugs Limited

Premium access

MSME payment history for Aarti Drugs Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Aarti Drugs Limited

Premium access

Corporate group structure for Aarti Drugs Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Aarti Drugs Limited

Premium access

MCA filings and documents for Aarti Drugs Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Aarti Drugs Limited

Activity
24 Sep 2025
Aarti Drugs Limited last Annual general meeting of members was held on 24 Sep 2025 as per latest MCA records.
Activity
31 Mar 2025
Aarti Drugs Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai.
Charges
20 Jun 2024
A charge registered on 25 Jan 2024 via Charge ID 100855330 with Others was fully satisfied on 20 Jun 2024.
Charges
11 Jun 2024
A charge with Axis Bank Limited of Rs. 1,570.00 Cr registered on 26 Mar 2011 with Charge ID 10277975 was modified on 11 Jun 2024.
Directors
29 Mar 2024
Sandeep Madhusudan Joshi was appointed as a Director on 29 Mar 2024 & has been associated with this company since 2 years 3 months.
Directors
29 Mar 2024
Hasmukh Bhavanji Dedhia was appointed as a Director on 29 Mar 2024 & has been associated with this company since 2 years 3 months.

Recent News on Aarti Drugs Limited

Stocks that will see action today: March 7, 2025
07 Mar 2025 · Thehindubusinessline
Stocks that will see action today: January 29
29 Jan 2025 · Thehindubusinessline

Frequently Asked Questions about Aarti Drugs Limited

Aarti Drugs Limited is an active public limited company in the chemicals and materials sector based in Dist Thane, Maharashtra, India. It was incorporated on 28 September 1984 (42+ years old) and is registered under CIN L37060MH1984PLC055433. Listed on BSE: 524348 and NSE: AARTIDRUGS. The company has 1,012 employees.

Aarti Drugs Limited reported revenue of ₹2,565.31 Cr for FY 2026 (up 7.47% YoY) based on consolidated NSE filings.

The current directors and KMP of Aarti Drugs Limited are:

The primary industry of Aarti Drugs Limited is chemicals and materials. The company specifically operates in specialty chemicals. The company is currently active in this sector.

Yes. Aarti Drugs Limited is listed on both BSE (code: 524348) and NSE (symbol: AARTIDRUGS).

Aarti Drugs Limited can be reached at the registered office: Plot No 198 Midc Tarapurtal.Palghar Village Pamtermbhi, Dist Thane, Maharashtra, India – 401506, or through the website aartidrugs.co.in.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available